Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Berlin – page 107

1 770 clinical trials in Berlin, Germany across 17 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Berlin at a glance
1 770
clinical trials
  • Research sites17
Type of trial
Recruitment status
Quick filters

1 770 trials in Berlin

Open in trial search

Study of RLS-0071 Treatment for Hospitalized Patients with Steroid-Resistant Acute Graft-versus-Host Disease (aGvHD)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ile-Ala-Leu-Ile-Leu-Glu-Pro-Ile-Cys-Cys-Gln-Glu-Arg-Ala-Ala-(Discrete-Polyethylene Glycol)24
  • Sponsor:Realta Life Sciences Inc.

B-cell lymphoma

Not recruiting

Study of Rituximab, Polatuzumab Vedotin, and Glofitamab for Untreated Aggressive B-cell Lymphoma in Patients Over 60 Not Eligible for Full R-CHOP

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study comparing chemotherapy with or without radiation therapy in patients with resectable gastroesophageal junction cancer using docetaxel, oxaliplatin, fluorouracil and calcium folinate

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Heidelberg University

Study on the Effects and Safety of Buloxibutid for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Buloxibutid
  • Sponsor:Vicore Pharma AB

Fallopian tube cancer+2

Not recruiting

Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Study of Ivosidenib and Azacitidine for Patients Aged 18 and Older with Untreated Acute Myeloid Leukemia with IDH1 Mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Cholangiocarcinoma+1

Not recruiting

Study on Gemcitabine and Cisplatin for Patients After Surgery for Bile Duct or Gallbladder Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:University Medical Center Hamburg-Eppendorf

Ovarian cancer

Not recruiting

Study of Olaparib, Durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alrefimotide
  • Sponsor:Nordic Society Of Gynaecological Oncology Clinical Trial Unit

Study of Vericiguat to improve physical function in patients with Post-COVID-19 syndrome with or without chronic fatigue syndrome

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Vericiguat
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Short-bowel syndrome

Not recruiting

Study on the Long-Term Safety and Effectiveness of Glepaglutide for Patients with Short Bowel Syndrome

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glepaglutide
  • Sponsor:Zealand Pharma A/S

Cold urticaria

Not recruiting

Study on the Effectiveness and Safety of Barzolvolimab for Patients with Chronic Inducible Urticaria

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Berlin

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on various cancer treatments, including studies of metastatic prostate cancer, colorectal cancer, and innovative approaches for breast cancer treatment.

  • Prostate Cancer Therapeutics
  • Colorectal Cancer Treatment
  • Early-Stage Breast Cancer
  • Bladder Cancer Interventions

Novel combination therapies and targeted treatments are being evaluated to improve patient outcomes across multiple cancer types.

02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting various viral infections, including studies on respiratory syncytial virus, cytomegalovirus, and herpes zoster.

  • RSV Vaccine Development
  • CMV Prevention
  • Yellow Fever Protection
  • Herpes Virus Management

These trials aim to enhance immune response and provide long-term protection against serious viral infections.

03 Chronic Conditions

Innovative treatments for various chronic conditions, including autoimmune dementia, hypertriglyceridemia, and studies in transplant medicine.

  • Neurological Disorders
  • Metabolic Conditions
  • Organ Transplantation
  • Women's Health

Research focuses on developing targeted therapies and improving treatment outcomes for long-term conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.